NEW YORK (GenomeWeb) – Biocept today announced that it has signed two new agreements with preferred provider organization networks — Fortified Provider Network and Three Rivers Provider Network.

Under the deals, the approximately 26 million members of these two PPOs will now have covered access to Biocept's Target Selector non-invasive liquid biopsy assays, which include tests for melanoma, breast, lung, and gastric cancer biomarkers.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.